ARTICLE | Company News

Movetis sales and marketing update

September 27, 2010 7:00 AM UTC

Movetis launched Resolor prucalopride in Belgium to treat chronic constipation in women not receiving adequate relief from laxatives. The company said it launched the serotonin (5-HT4) receptor agonist prior to receiving reimbursement approval from Belgian health care insurance authority, but is preparing to file for reimbursement status. The public price for a 28-tablet pack is €75.50 ($96.70) and €61.60 ($78.90) for the 2 and 1 mg dose, respectively. The recommended dose for Resolor is a 2 mg tablet given once daily. ...